What are the therapeutic strategies targeting VEGF in cancer?
Several therapeutic strategies are designed to target VEGF in cancer, aiming to inhibit tumor angiogenesis. These include:
Monoclonal antibodies: Bevacizumab (Avastin) is a well-known monoclonal antibody that specifically binds to VEGF, preventing it from interacting with its receptors. Tyrosine kinase inhibitors: These drugs, such as sunitinib and sorafenib, inhibit the VEGF receptors' tyrosine kinase activity, blocking signal transduction pathways involved in angiogenesis. VEGF-trap: Aflibercept (Zaltrap) acts as a decoy receptor, binding to VEGF and preventing it from activating VEGF receptors on endothelial cells.
